{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:29:55Z","timestamp":1792877395440,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The objective of this multicenter study was to compare the diagnostic performance of lateral flow assay (LFA) and enzyme-linked immunosorbent assay (ELISA) to detect the Dynamiker <jats:italic>Aspergillus<\/jats:italic> Galactomannan levels in serum and bronchoalveolar lavage fluid (BALF) samples for I.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We registered 310 clinically suspected <jats:italic>Aspergillus<\/jats:italic> infection patients from December 2021 to February 2023 and classified them into subgroups as the \u201cIA group\u201d and \u201cnon-IA group\u201d based on the latest EORTC\/MSG guidelines. The immunoassays were analyzed by LFA and ELISA respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Galactomannan was examined using LFA, and serum and BALF samples demonstrated sensitivities of 82.57% and 89.47%, specificities of 90.76% and 92.00%, PPVs of 89.11% and 96.23%, and NPVs of 85.04% and 79.31%, respectively. Galactomannan was observed using two assays in serum and BALF samples and showed PPAs of 95.11% and 93.33%, NPAs of 89.19% and 96.30%, and TPAs of 92.47% and 94.25%, respectively. The ROC curve demonstrated that LFA had optimum diagnostic value when the index value (<jats:italic>I<\/jats:italic> value) = 0.5, the sensitivity was 84.94%, and the specificity was 90.97%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Compared to the ELISA method, the LFA has shown excellent performance for the diagnosis of IA in serum and BALF sample and can be used as an assay for the early diagnosis of patients with IA. The dynamic change in galactomannan levels may be useful for assessing treatment response.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10096-023-04724-4","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:03:20Z","timestamp":1701302600000},"page":"249-257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Performance of the Aspergillus galactomannan lateral flow assay with a digital reader for the diagnosis of invasive aspergillosis: a multicenter study"],"prefix":"10.1007","volume":"43","author":[{"given":"Jian","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-3179","authenticated-orcid":false,"given":"Wenjuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"4724_CR1","unstructured":"Global Action Fund for Fungal Infections (2022) Country fungal disease burdens. https:\/\/gaffi.org\/media\/country-fungal-disease-burdens\/.n.d. Accessed 7 Oct 2022"},{"key":"4724_CR2","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.3201\/eid2609.200016","volume":"26","author":"L-H Zhou","year":"2020","unstructured":"Zhou L-H, Jiang Y-K, Li R-Y et al (2020) Risk-based estimate of human fungal disease burden, China. Emerg Infect Dis 26:2137\u20132147. https:\/\/doi.org\/10.3201\/eid2609.200016","journal-title":"Emerg Infect Dis"},{"key":"4724_CR3","unstructured":"Chinese State Statistical Bureau (2018) China statistical yearbook. http:\/\/www.stats.gov.cn\/tjsj\/ndsj\/2018\/indexch.htm.n.d. Accessed 7 Oct 2022"},{"key":"4724_CR4","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(18)30841-9","volume":"391","author":"C Wang","year":"2018","unstructured":"Wang C, Xu J, Yang L et al (2018) Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet 391:1706\u20131717. https:\/\/doi.org\/10.1016\/S0140-6736(18)30841-9","journal-title":"Lancet"},{"key":"4724_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jinf.2020.03.065","volume":"81","author":"M Bassetti","year":"2020","unstructured":"Bassetti M, Giacobbe DR, Grecchi C et al (2020) Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: a systematic review with qualitative evidence synthesis. J Infect 81:131\u2013146. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.065","journal-title":"J Infect"},{"key":"4724_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/jof2030022","volume":"2","author":"F Lamoth","year":"2016","unstructured":"Lamoth F (2016) Galactomannan and 1,3-\u03b2-d-glucan testing for the diagnosis of invasive aspergillosis. J Fungi 2:22. https:\/\/doi.org\/10.3390\/jof2030022","journal-title":"J Fungi"},{"key":"4724_CR7","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA et al (2020) Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the mycoses Study Group Education and Research Consortium. Clin Infect Dis 71:1367\u20131376. https:\/\/doi.org\/10.1093\/cid\/ciz1008","journal-title":"Clin Infect Dis"},{"key":"4724_CR8","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/14737159.2020.1820864","volume":"20","author":"JD Jenks","year":"2020","unstructured":"Jenks JD, Hoenigl M (2020) Point-of-care diagnostics for invasive aspergillosis: nearing the finish line. Expert Rev Mol Diagn 20:1009\u20131017. https:\/\/doi.org\/10.1080\/14737159.2020.1820864","journal-title":"Expert Rev Mol Diagn"},{"key":"4724_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/myc.12881","volume":"62","author":"JD Jenks","year":"2019","unstructured":"Jenks JD, Mehta SR, Taplitz R et al (2019) Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: Aspergillus Galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test in bronchoalveolar lavage. Mycoses 62:230\u2013236. https:\/\/doi.org\/10.1111\/myc.12881","journal-title":"Mycoses"},{"key":"4724_CR10","doi-asserted-by":"publisher","first-page":"e00053","DOI":"10.1128\/JCM.00053-20","volume":"58","author":"PL White","year":"2020","unstructured":"White PL, Price JS, Posso R et al (2020) Evaluation of the performance of the IMMY sona Aspergillus Galactomannan lateral flow assay when testing serum to aid in diagnosis of invasive aspergillosis. J Clin Microbiol 58:e00053\u2013e00020. https:\/\/doi.org\/10.1128\/JCM.00053-20","journal-title":"J Clin Microbiol"},{"key":"4724_CR11","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1177\/0300060519874901","volume":"47","author":"L Zhang","year":"2019","unstructured":"Zhang L, Che C (2019) Clinical manifestations and outcome analysis of invasive pulmonary aspergillosis infection: a retrospective study in 43 nonneutropenic patients. J Int Med Res 47:5680\u20135688. https:\/\/doi.org\/10.1177\/0300060519874901","journal-title":"J Int Med Res"},{"key":"4724_CR12","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/jim-2021-001857","volume":"69","author":"F Liu","year":"2021","unstructured":"Liu F, Zhang X, Du W et al (2021) Diagnosis values of IL-6 and IL-8 levels in serum and bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in chronic obstructive pulmonary disease. J Investig Med 69:1344\u20131349. https:\/\/doi.org\/10.1136\/jim-2021-001857","journal-title":"J Investig Med"},{"key":"4724_CR13","doi-asserted-by":"publisher","first-page":"101330","DOI":"10.1016\/j.mycmed.2022.101330","volume":"33","author":"Y Zhong","year":"2023","unstructured":"Zhong Y, Ji T, Qin D, Cheng D (2023) Clinical characteristics and risk factors of in-hospital mortality in patients coinfected with Pneumocystis jirovecii and Aspergillus. J Med Mycol 33:101330. https:\/\/doi.org\/10.1016\/j.mycmed.2022.101330","journal-title":"J Med Mycol"},{"key":"4724_CR14","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/myc.12679","volume":"60","author":"S Heldt","year":"2017","unstructured":"Heldt S, Eigl S, Prattes J et al (2017) Levels of interleukin (IL)-6 and IL-8 are elevated in serum and bronchoalveolar lavage fluid of haematological patients with invasive pulmonary aspergillosis. Mycoses 60:818\u2013825. https:\/\/doi.org\/10.1111\/myc.12679","journal-title":"Mycoses"},{"key":"4724_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1469-0691.2008.02122.x","volume":"15","author":"C Cordonnier","year":"2009","unstructured":"Cordonnier C, Botterel F, Ben Amor R et al (2009) Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect 15:81\u201386. https:\/\/doi.org\/10.1111\/j.1469-0691.2008.02122.x","journal-title":"Clin Microbiol Infect"},{"key":"4724_CR16","doi-asserted-by":"publisher","first-page":"e23806","DOI":"10.1002\/jcla.23806","volume":"35","author":"H Susianti","year":"2021","unstructured":"Susianti H, Parmadi L, Firani NK et al (2021) Diagnostic value of serum human Galactomannan aspergillus antigen and 1,3-beta-D-glucan in immunocompromised patient suspected fungal infection. J Clin Lab Anal 35:e23806. https:\/\/doi.org\/10.1002\/jcla.23806","journal-title":"J Clin Lab Anal"},{"key":"4724_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jinf.2018.10.014","volume":"78","author":"JD Jenks","year":"2019","unstructured":"Jenks JD, Mehta SR, Taplitz R et al (2019) Bronchoalveolar lavage Aspergillus Galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test for diagnosis of invasive pulmonary Aspergillosis in patients with hematological malignancies. J Infect 78:249\u2013259. https:\/\/doi.org\/10.1016\/j.jinf.2018.10.014","journal-title":"J Infect"},{"key":"4724_CR18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/mmy\/myz079","volume":"58","author":"T Mercier","year":"2020","unstructured":"Mercier T, Dunbar A, de Kort E et al (2020) Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: a comparative multicenter study. Med Mycol 58:444\u2013452. https:\/\/doi.org\/10.1093\/mmy\/myz079","journal-title":"Med Mycol"},{"key":"4724_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/myc.13265","volume":"64","author":"I Serin","year":"2021","unstructured":"Serin I, Dogu MH (2021) Serum Aspergillus galactomannan lateral flow assay for the diagnosis of invasive aspergillosis: a single-centre study. Mycoses 64:678\u2013683. https:\/\/doi.org\/10.1111\/myc.13265","journal-title":"Mycoses"},{"key":"4724_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/jof8070741","volume":"8","author":"R Almeida-Paes","year":"2022","unstructured":"Almeida-Paes R, Almeida MD, de Macedo PM et al (2022) Performance of two commercial assays for the detection of serum aspergillus galactomannan in non-neutropenic patients. J Fungi 8:741. https:\/\/doi.org\/10.3390\/jof8070741","journal-title":"J Fungi"},{"key":"4724_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/jof6040297","volume":"6","author":"KA Linder","year":"2020","unstructured":"Linder KA, Kauffman CA, Miceli MH (2020) Performance of Aspergillus Galactomannan lateral flow assay on bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis. J Fungi 6:297. https:\/\/doi.org\/10.3390\/jof6040297","journal-title":"J Fungi"},{"key":"4724_CR22","doi-asserted-by":"publisher","first-page":"e01006","DOI":"10.1128\/JCM.01006-20","volume":"58","author":"PL White","year":"2020","unstructured":"White PL, Price JS, Posso R et al (2020) An evaluation of the performance of the IMMY Aspergillus Galactomannan enzyme-linked immunosorbent assay when testing serum to aid in the diagnosis of invasive aspergillosis. J Clin Microbiol 58:e01006\u2013e01020. https:\/\/doi.org\/10.1128\/JCM.01006-20","journal-title":"J Clin Microbiol"},{"key":"4724_CR23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR, Denning DW et al (2016) Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63:e1\u2013e60. https:\/\/doi.org\/10.1093\/cid\/ciw326","journal-title":"Clin Infect Dis"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04724-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-023-04724-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04724-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T21:38:10Z","timestamp":1706391490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-023-04724-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["4724"],"URL":"https:\/\/doi.org\/10.1007\/s10096-023-04724-4","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"6 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the ethics committee of Ruijin Hospital, Shanghai Jiaotong University School of Medicine (codeRJ2022246). This study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"A waiver of informed consent was granted by the committee owing to the use of remnant and de-identifed samples for the study. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}